Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 12/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.40 |
| ▸ | KDR | P35968 | 8/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 7/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.40 |
| ▸ | FLT3 | P36888 | 5/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22036509 | 0.91 | CSF1R (0.40) | CSF1RPDGFRAPDGFRBKDRFGFR1 | |
| SCHEMBL22036855 | 0.89 | CSF1R (0.41) | CSF1RPDGFRAPDGFRBKDRFGFR1 | |
| SCHEMBL21824004 | 0.88 | CSF1R (0.57) | CSF1RPDGFRAPDGFRBKDRFLT3 | |
| SCHEMBL30673534 | 0.88 | CSF1R (0.57) | CSF1RPDGFRAPDGFRBKDRFLT3 | |
| SCHEMBL22036036 | 0.87 | FGFR1 (0.37) | CSF1RPDGFRAKDRFGFR1FGFR3 | |
| SCHEMBL22036035 | 0.84 | MDM2 (0.36) | CSF1RPDGFRAKDRFGFR1FGFR3 | |
| SCHEMBL21824018 | 0.83 | CSF1R (0.58) | CSF1RPDGFRAPDGFRBKDRFLT3 | |
| SCHEMBL21824023 | 0.79 | CSF1R (0.54) | CSF1RPDGFRAPDGFRBKDRFLT3 | |
| SCHEMBL21824030 | 0.79 | CSF1R (0.54) | CSF1RPDGFRAPDGFRBKDRFLT3 | |
| SCHEMBL21824013 | 0.79 | CSF1R (0.53) | CSF1RPDGFRAPDGFRBKDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130762-B2 | Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-09-28 | — | — | US | disclosed |
| US-20200165254-A1 | AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165254-A1 | AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY | FAR1, CSF1R, CSF3R | CSF1R 2/4885PDGFRA 977/4885PDGFRB 891/4885 |
| US-11130762-B2 | Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy | FAR1, CSF1R, CSF3R | CSF1R 2/4885PDGFRA 977/4885PDGFRB 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.